Skip to main content
Top
Published in: BMC Infectious Diseases 1/2017

Open Access 01-12-2017 | Research article

Is the impact of childhood influenza vaccination less than expected: a transmission modelling study

Authors: Felix Weidemann, Cornelius Remschmidt, Silke Buda, Udo Buchholz, Bernhard Ultsch, Ole Wichmann

Published in: BMC Infectious Diseases | Issue 1/2017

Login to get access

Abstract

Background

To reduce the burden of severe influenza, most industrialized countries target specific risk-groups with influenza vaccines, e.g. the elderly or individuals with comorbidities. Since children are the main spreaders, some countries have recently implemented childhood vaccination programs to reduce overall virus transmission and thereby influenza disease in the whole population. The introduction of childhood vaccination programs was often supported by modelling studies that predicted substantial incidence reductions. We developed a mathematical transmission model to examine the potential impact of childhood influenza vaccination in Germany, while also challenging established modelling assumptions.

Methods

We developed an age-stratified SEIR-type transmission model to reproduce the epidemic influenza seasons between 2003/04 and 2013/14. The model was built upon German population counts, contact patterns, and vaccination history and was fitted to seasonal data on influenza-attributable medically attended acute respiratory infections (I-MAARI) and strain distribution using Bayesian methods. As novelties we (i) implemented a stratified model structure enabling seasonal variability and (ii) deviated from the commonly assumed mass-action-principle by employing a phenomenological transmission rate.

Results

According to the model, by vaccinating primarily the elderly over ten seasons 4 million (95% prediction interval: 3.84 – 4.19) I-MAARI were prevented which corresponds to an 8.6% (8.3% – 8.9%) reduction compared to a no-vaccination scenario and a number-needed-to-vaccinate (NNV) to prevent one I-MAARI of 37.1 (35.5 – 38.7). Additional vaccination of 2-10 year-old children at 40% coverage would have led to an overall I-MAARI reduction of 17.8% (17.1 – 18.7%) mostly due to indirect effects with a NNV of 20.7 (19.6 – 21.6). When employing the traditional mass-action-principle, the model predicted a more than 3-fold higher I-MAARI reduction (55.6%) due to childhood vaccination.

Conclusion

In Germany, the introduction of routine childhood influenza vaccination could considerably reduce I-MAARI among all age-groups and improve the NNV. However, the predicted impact is much lower compared to previous studies, which is primarily caused by our phenomenological approach to modelling influenza virus transmission.
Appendix
Available only for authorised users
Literature
1.
go back to reference Neuzil KM, Hohlbein C, Zhu Y. Illness among schoolchildren during influenza season: Effect on school absenteeism, parental absenteeism from work, and secondary illness in families. Arch Pediatr Adolesc Med. 2002;156(10):986–91.CrossRefPubMed Neuzil KM, Hohlbein C, Zhu Y. Illness among schoolchildren during influenza season: Effect on school absenteeism, parental absenteeism from work, and secondary illness in families. Arch Pediatr Adolesc Med. 2002;156(10):986–91.CrossRefPubMed
2.
go back to reference Monto AS, Sullivan KM. Acute respiratory illness in the community. Frequency of illness and the agents involved. Epidemiol Infect. 1993;110(1):145–60.CrossRefPubMedPubMedCentral Monto AS, Sullivan KM. Acute respiratory illness in the community. Frequency of illness and the agents involved. Epidemiol Infect. 1993;110(1):145–60.CrossRefPubMedPubMedCentral
3.
go back to reference WHO. Influenza vaccines—WHO position paper. Wkly Epidemiol Rec. 2005;33:279–87. WHO. Influenza vaccines—WHO position paper. Wkly Epidemiol Rec. 2005;33:279–87.
5.
go back to reference Michiels B, et al. A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups. Vaccine. 2011;29(49):9159–70.CrossRefPubMed Michiels B, et al. A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups. Vaccine. 2011;29(49):9159–70.CrossRefPubMed
6.
go back to reference Jefferson, T., et al., Vaccines for preventing influenza in healthy adults, in Cochrane Database Syst Rev. 2010. Jefferson, T., et al., Vaccines for preventing influenza in healthy adults, in Cochrane Database Syst Rev. 2010.
7.
go back to reference Reichert TA, et al. The Japanese Experience with Vaccinating Schoolchildren against Influenza. N Engl J Med. 2001;344(12):889–96.CrossRefPubMed Reichert TA, et al. The Japanese Experience with Vaccinating Schoolchildren against Influenza. N Engl J Med. 2001;344(12):889–96.CrossRefPubMed
8.
go back to reference Grohskopf LA, et al. Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices. Morb Mortal Wkly Rep. 2015;64(30):818–25.CrossRef Grohskopf LA, et al. Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices. Morb Mortal Wkly Rep. 2015;64(30):818–25.CrossRef
9.
go back to reference Pebody, R.G., et al., Uptake and impact of vaccinating school age children against influenza during a season with circulation of drifted influenza A and B strains, England, 2014/15. Euro Surveill, 2015. 20(39). Pebody, R.G., et al., Uptake and impact of vaccinating school age children against influenza during a season with circulation of drifted influenza A and B strains, England, 2014/15. Euro Surveill, 2015. 20(39).
10.
go back to reference Loeb M, et al. Effect of influenza vaccination of children on infection rates in hutterite communities: A randomized trial. JAMA. 2010;303(10):943–50.CrossRefPubMed Loeb M, et al. Effect of influenza vaccination of children on infection rates in hutterite communities: A randomized trial. JAMA. 2010;303(10):943–50.CrossRefPubMed
11.
go back to reference Spier R, et al. 3rd Vaccine Global Congress, Singapore 2009. Assessing Herd Immunity in the Elderly Following the Vaccination of School Children with Live Attenuated Trivalent Influenza Vaccine (LAIV): A County-Level Analysis. Proc Vaccinol. 2010;2(1):92–100.CrossRef Spier R, et al. 3rd Vaccine Global Congress, Singapore 2009. Assessing Herd Immunity in the Elderly Following the Vaccination of School Children with Live Attenuated Trivalent Influenza Vaccine (LAIV): A County-Level Analysis. Proc Vaccinol. 2010;2(1):92–100.CrossRef
13.
go back to reference Rhorer J, et al. Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials. Vaccine. 2009;27(7):1101–10.CrossRefPubMed Rhorer J, et al. Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials. Vaccine. 2009;27(7):1101–10.CrossRefPubMed
14.
go back to reference Flannery B. LAIV vs IIV effectiveness: Summary of evidence since 2009. In: Presented at: Centers for Disease Control and Prevention Advisory Committee on Immunization Practices (ACIP) Meeting; 2016 Jun 22–23; Atlanta, GA; 2016. Flannery B. LAIV vs IIV effectiveness: Summary of evidence since 2009. In: Presented at: Centers for Disease Control and Prevention Advisory Committee on Immunization Practices (ACIP) Meeting; 2016 Jun 22–23; Atlanta, GA; 2016.
15.
go back to reference Centers for Disease Control and Prevention. ACIP votes down use of LAIV for 2016-2017 flu season. 2016. Centers for Disease Control and Prevention. ACIP votes down use of LAIV for 2016-2017 flu season. 2016.
16.
go back to reference Baguelin M, et al. Assessing Optimal Target Populations for Influenza Vaccination Programmes: An Evidence Synthesis and Modelling Study. PLoS Med. 2013;10(10):e1001527.CrossRefPubMedPubMedCentral Baguelin M, et al. Assessing Optimal Target Populations for Influenza Vaccination Programmes: An Evidence Synthesis and Modelling Study. PLoS Med. 2013;10(10):e1001527.CrossRefPubMedPubMedCentral
17.
go back to reference Vynnycky E, et al. Estimating the impact of childhood influenza vaccination programmes in England and Wales. Vaccine. 2008;26(41):5321–30.CrossRefPubMed Vynnycky E, et al. Estimating the impact of childhood influenza vaccination programmes in England and Wales. Vaccine. 2008;26(41):5321–30.CrossRefPubMed
18.
go back to reference Rose MA, et al. The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study. BMC Infect Dis. 2014;14:40-40. Rose MA, et al. The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study. BMC Infect Dis. 2014;14:40-40.
20.
go back to reference an der Heiden M, et al. Estimates of Excess Medically Attended Acute Respiratory Infections in Periods of Seasonal and Pandemic Influenza in Germany from 2001/02 to 2010/11. PLoS One. 2013;8(7):e64593.CrossRef an der Heiden M, et al. Estimates of Excess Medically Attended Acute Respiratory Infections in Periods of Seasonal and Pandemic Influenza in Germany from 2001/02 to 2010/11. PLoS One. 2013;8(7):e64593.CrossRef
21.
go back to reference Buda S, et al. Bericht zur in Deutschland Saison 2013/14. Berlin: Robert Koch-Institut; 2014. Buda S, et al. Bericht zur in Deutschland Saison 2013/14. Berlin: Robert Koch-Institut; 2014.
22.
go back to reference Buchholz, U., A. Grüber, and B. Schweiger. Abschlussbericht der Influenzasaison. Robert Koch-Institut Buchholz, U., A. Grüber, and B. Schweiger. Abschlussbericht der Influenzasaison. Robert Koch-Institut
23.
go back to reference STIKO. Statement of the German Standing Committee on Vaccination at the RKI: Recommendations of the Standing Committee on Vaccination (STIKO) at the Robert Koch Institute. Epidemiol Bull. 2015;34:327–62. STIKO. Statement of the German Standing Committee on Vaccination at the RKI: Recommendations of the Standing Committee on Vaccination (STIKO) at the Robert Koch Institute. Epidemiol Bull. 2015;34:327–62.
24.
go back to reference Rieck T, et al. Vaccination coverage among children in Germany estimated by analysis of health insurance claims data. Hum Vaccin Immunother. 2014;10(2):476–84.CrossRefPubMed Rieck T, et al. Vaccination coverage among children in Germany estimated by analysis of health insurance claims data. Hum Vaccin Immunother. 2014;10(2):476–84.CrossRefPubMed
25.
go back to reference Jefferson, T., et al., Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev, 2010 (7). Jefferson, T., et al., Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev, 2010 (7).
26.
go back to reference Jefferson, T., et al., Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev, 2008(2). Jefferson, T., et al., Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev, 2008(2).
27.
go back to reference Kissling, E., et al., Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case-control study, influenza season 2012/13. Euro Surveill. 2014, 19(6). Kissling, E., et al., Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case-control study, influenza season 2012/13. Euro Surveill. 2014, 19(6).
28.
go back to reference Kissling E, et al. I-MOVE Multi-Centre Case Control Study 2010-11: Overall and Stratified Estimates of Influenza Vaccine Effectiveness in Europe. PLoS One. 2011;6(11):e27622.CrossRefPubMedPubMedCentral Kissling E, et al. I-MOVE Multi-Centre Case Control Study 2010-11: Overall and Stratified Estimates of Influenza Vaccine Effectiveness in Europe. PLoS One. 2011;6(11):e27622.CrossRefPubMedPubMedCentral
29.
go back to reference Kissling, E., et al., "I-MOVE" towards monitoring seasonal and pandemic influenza vaccine effectiveness: lessons learnt from a pilot multi-centric case-control study in Europe, 2008-9. Euro Surveill, 2009. 14(44). Kissling, E., et al., "I-MOVE" towards monitoring seasonal and pandemic influenza vaccine effectiveness: lessons learnt from a pilot multi-centric case-control study in Europe, 2008-9. Euro Surveill, 2009. 14(44).
30.
go back to reference Kissling, E., et al., Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study. Euro Surveill. 18(5). Kissling, E., et al., Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study. Euro Surveill. 18(5).
31.
go back to reference Valenciano M, et al. Estimates of Pandemic Influenza Vaccine Effectiveness in Europe, 2009–2010: Results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) Multicentre Case-Control Study. PLoS Med. 2011;8(1):e1000388.CrossRefPubMedPubMedCentral Valenciano M, et al. Estimates of Pandemic Influenza Vaccine Effectiveness in Europe, 2009–2010: Results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) Multicentre Case-Control Study. PLoS Med. 2011;8(1):e1000388.CrossRefPubMedPubMedCentral
32.
go back to reference Valenciano M, et al. The European I-MOVE Multicentre 2013–2014. Case-Control Study. Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogenous results by country against A(H3N2). Vaccine. 2015;33(24):2813–22.CrossRefPubMed Valenciano M, et al. The European I-MOVE Multicentre 2013–2014. Case-Control Study. Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogenous results by country against A(H3N2). Vaccine. 2015;33(24):2813–22.CrossRefPubMed
33.
go back to reference Langley JM, et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children. J Infect Dis. 2013;208(4):544–53.CrossRefPubMedPubMedCentral Langley JM, et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children. J Infect Dis. 2013;208(4):544–53.CrossRefPubMedPubMedCentral
34.
go back to reference Tricco AC, et al. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC Med. 2013;11(1):1–19.CrossRef Tricco AC, et al. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC Med. 2013;11(1):1–19.CrossRef
35.
go back to reference Eichner M, et al. 4Flu - an individual based simulation tool to study the effects of quadrivalent vaccination on seasonal influenza in Germany. BMC Infect Dis. 2014;14:365-365.CrossRef Eichner M, et al. 4Flu - an individual based simulation tool to study the effects of quadrivalent vaccination on seasonal influenza in Germany. BMC Infect Dis. 2014;14:365-365.CrossRef
36.
go back to reference Goeyvaerts N, et al. Estimating dynamic transmission model parameters for seasonal influenza by fitting to age and season-specific influenza-like illness incidence. Epidemics. 2015;13:1–9.CrossRefPubMed Goeyvaerts N, et al. Estimating dynamic transmission model parameters for seasonal influenza by fitting to age and season-specific influenza-like illness incidence. Epidemics. 2015;13:1–9.CrossRefPubMed
37.
go back to reference Pitman RJ, White LJ, Sculpher M. Estimating the clinical impact of introducing paediatric influenza vaccination in England and Wales. Vaccine. 2012;30(6):1208–24.CrossRefPubMed Pitman RJ, White LJ, Sculpher M. Estimating the clinical impact of introducing paediatric influenza vaccination in England and Wales. Vaccine. 2012;30(6):1208–24.CrossRefPubMed
38.
go back to reference Ultsch B, et al. Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community. PharmacoEconomics. 2016;34:227–44.CrossRefPubMed Ultsch B, et al. Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community. PharmacoEconomics. 2016;34:227–44.CrossRefPubMed
39.
go back to reference Gelman A, Hill J. Data analysis using regression and multilevel/hierarchical models. Cambridge: Cambridge University Press; 2006. Gelman A, Hill J. Data analysis using regression and multilevel/hierarchical models. Cambridge: Cambridge University Press; 2006.
40.
go back to reference Finkenstädt BF, Grenfell BT. Time series modelling of childhood diseases: a dynamical systems approach. J R Stat Soc: Ser C: Appl Stat. 2000;49(2):187–205.CrossRef Finkenstädt BF, Grenfell BT. Time series modelling of childhood diseases: a dynamical systems approach. J R Stat Soc: Ser C: Appl Stat. 2000;49(2):187–205.CrossRef
41.
go back to reference McCallum H, Barlow N, Hone J. How should pathogen transmission be modelled? Trends Ecol Evol. 2001;16(6):295–300.CrossRefPubMed McCallum H, Barlow N, Hone J. How should pathogen transmission be modelled? Trends Ecol Evol. 2001;16(6):295–300.CrossRefPubMed
42.
go back to reference Chowell G, et al. Characterizing the reproduction number of epidemics with early subexponential growth dynamics. J R Soc Interface. 2016;13 Chowell G, et al. Characterizing the reproduction number of epidemics with early subexponential growth dynamics. J R Soc Interface. 2016;13
43.
go back to reference Kong, L., et al., Modeling Heterogeneity in Direct Infectious Disease Transmission in a Compartmental Model. Int J Environ Res Public Health, 2016. 13(3). Kong, L., et al., Modeling Heterogeneity in Direct Infectious Disease Transmission in a Compartmental Model. Int J Environ Res Public Health, 2016. 13(3).
45.
go back to reference Goeyvaerts N, et al. Estimating Infectious Disease Parameters from Data on Social Contacts and Serological Status. J Royal Stat Soc Ser C Appl Stat. 2010;59(2):255–77.CrossRef Goeyvaerts N, et al. Estimating Infectious Disease Parameters from Data on Social Contacts and Serological Status. J Royal Stat Soc Ser C Appl Stat. 2010;59(2):255–77.CrossRef
46.
go back to reference Hermes J, et al. Lack of evidence for pre-symptomatic transmission of pandemic influenza virus A(H1N1) 2009 in an outbreak among teenagers; Germany, 2009. Influenza Other Respir Viruses. 2011;5(6):e499–503.CrossRefPubMed Hermes J, et al. Lack of evidence for pre-symptomatic transmission of pandemic influenza virus A(H1N1) 2009 in an outbreak among teenagers; Germany, 2009. Influenza Other Respir Viruses. 2011;5(6):e499–503.CrossRefPubMed
47.
go back to reference Eames K, et al. The impact of illness and the impact of school closure on social contact patterns. Health Technol Assess. 2010:14(34). Eames K, et al. The impact of illness and the impact of school closure on social contact patterns. Health Technol Assess. 2010:14(34).
48.
go back to reference Van Kerckhove K, et al. The Impact of Illness on Social Networks: Implications for Transmission and Control of Influenza. Am J Epidemiol. 2013;178(11):1655–62.CrossRefPubMedPubMedCentral Van Kerckhove K, et al. The Impact of Illness on Social Networks: Implications for Transmission and Control of Influenza. Am J Epidemiol. 2013;178(11):1655–62.CrossRefPubMedPubMedCentral
49.
go back to reference Carrat F, et al. Time Lines of Infection and Disease in Human Influenza: A Review of Volunteer Challenge Studies. Am J Epidemiol. 2008;167(7):775–85.CrossRefPubMed Carrat F, et al. Time Lines of Infection and Disease in Human Influenza: A Review of Volunteer Challenge Studies. Am J Epidemiol. 2008;167(7):775–85.CrossRefPubMed
50.
go back to reference Weidemann F, et al. Modelling the epidemiological impact of rotavirus vaccination in Germany – A Bayesian approach. Vaccine. 2014;32(40):5250–7.CrossRefPubMed Weidemann F, et al. Modelling the epidemiological impact of rotavirus vaccination in Germany – A Bayesian approach. Vaccine. 2014;32(40):5250–7.CrossRefPubMed
51.
go back to reference Kass RE, Raftery AE. Bayes Factors. J Am Stat Assoc. 1995;90(430):773–95.CrossRef Kass RE, Raftery AE. Bayes Factors. J Am Stat Assoc. 1995;90(430):773–95.CrossRef
52.
go back to reference Hardelid, P., et al., Assessment of baseline age-specific antibody prevalence and incidence of infection to novel influenza A H1N1 2009. Health Technol Assess, 2011. 14(55). Hardelid, P., et al., Assessment of baseline age-specific antibody prevalence and incidence of infection to novel influenza A H1N1 2009. Health Technol Assess, 2011. 14(55).
53.
go back to reference Dudareva S, et al. Prevalence of Antibodies to 2009 Pandemic Influenza A (H1N1) Virus in German Adult Population in Pre- and Post-Pandemic Period. PLoS One. 2011;6(6):e21340.CrossRefPubMedPubMedCentral Dudareva S, et al. Prevalence of Antibodies to 2009 Pandemic Influenza A (H1N1) Virus in German Adult Population in Pre- and Post-Pandemic Period. PLoS One. 2011;6(6):e21340.CrossRefPubMedPubMedCentral
54.
go back to reference Basta NE, et al. Strategies for Pandemic and Seasonal Influenza Vaccination of Schoolchildren in the United States. Am J Epidemiol. 2009;170(6):679–86.CrossRefPubMedPubMedCentral Basta NE, et al. Strategies for Pandemic and Seasonal Influenza Vaccination of Schoolchildren in the United States. Am J Epidemiol. 2009;170(6):679–86.CrossRefPubMedPubMedCentral
55.
go back to reference Bayer, C., et al., Internet-based syndromic monitoring of acute respiratory illness in the general population of Germany, weeks 35/2011 to 34/2012. Euro Surveill., 2014 19(4). Bayer, C., et al., Internet-based syndromic monitoring of acute respiratory illness in the general population of Germany, weeks 35/2011 to 34/2012. Euro Surveill., 2014 19(4).
Metadata
Title
Is the impact of childhood influenza vaccination less than expected: a transmission modelling study
Authors
Felix Weidemann
Cornelius Remschmidt
Silke Buda
Udo Buchholz
Bernhard Ultsch
Ole Wichmann
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2017
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-017-2344-6

Other articles of this Issue 1/2017

BMC Infectious Diseases 1/2017 Go to the issue